The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis

Basit Öğe Kaydı
dc.authorwosidYilmaz, Gulay/AAP-1142-2020
dc.contributor.authorSevinc, Can
dc.contributor.authorYilmaz, Gulay
dc.contributor.authorUstundag, Sedat
dc.date.accessioned2024-06-12T10:56:25Z
dc.date.available2024-06-12T10:56:25Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAim We aimed to investigate the factors affecting the development of atherosclerosis and the role of calcification inhibitors fetuin-A, matrix-Gla protein (MGP), osteoprotegerin (OPG) in atherosclerosis progress. Material and methods The study was planned to investigate the relationship of serum OPG, MGP and fetuin-A levels with the development of atherosclerosis in the stage 2-3-4-5 chronic kidney disease (CKD) patients who did not require dialysis treatment. Results 32 (17 female, 15 male) healthy individuals and 92 (49 females, 43 males) CKD patients were included. The mean carotid intima-media thickness (CIMT), C-reactive protein (CRP), fetuin-A, OPG and MGP of the two groups were compared statistically. In CKD patients, age, body mass index (BMI), CRP, triglyceride, urea, systolic blood pressure (SBP), fasting blood sugar have a positive linear relationship, fetuin-A, OPG, GFR have a negative linear relationship with CIMT. The mean CIMT, right CIMT, left CIMT, blood urea, CRP, urinary albumin excretion creatinine and age show a negative linear relationship with fetuin-A. Conclusion Fetuin-A levels begin to decline from the early stages of CKD and are significantly lower in patients with atherosclerosis as expressed with CIMT. This suggests that fetuin-A may be used as an early marker in CKD for increased cardiovascular risk. Early recognition of these risk factors is important and large-scale studies on vascular calcification inhibitors are needed.en_US
dc.identifier.doi10.1080/0886022X.2021.1969248
dc.identifier.endpage1358en_US
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue1en_US
dc.identifier.pmid34583616en_US
dc.identifier.scopus2-s2.0-85116165613en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1349en_US
dc.identifier.urihttps://doi.org/10.1080/0886022X.2021.1969248
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19787
dc.identifier.volume43en_US
dc.identifier.wosWOS:000701269900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Kidney Diseaseen_US
dc.subjectAtherosclerosisen_US
dc.subjectVascular Calcification Inhibitorsen_US
dc.subjectCarotid Intima Media Thicknessen_US
dc.subjectCoronary-Artery-Diseaseen_US
dc.subjectIntima-Media Thicknessen_US
dc.subjectMatrix Gla Proteinen_US
dc.subjectSerum Fetuin-Aen_US
dc.subjectVascular Calcificationen_US
dc.subjectCardiovascular-Diseaseen_US
dc.subjectRisk-Factorsen_US
dc.subjectMortalityen_US
dc.subjectMalnutritionen_US
dc.subjectInflammationen_US
dc.titleThe relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu